Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.46 |
| ▸ | PFKFB3 | Q16875 | 3/20 | 0.44 |
| ▸ | PFKFB4 | Q16877 | 3/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7018255 | 0.84 | MAPT (0.59) | MAPTKEAP1NFE2L2PFKFB3PFKFB4 | |
| SCHEMBL11801122 | 0.83 | KEAP1 (0.54) | MAPTKEAP1NFE2L2PTGDR2PFKFB4 | |
| SCHEMBL11797301 | 0.81 | KEAP1 (0.49) | MAPTKEAP1NFE2L2PTGDR2L3MBTL1 | |
| SCHEMBL10091955 | 0.79 | MAPT (0.56) | MAPTPFKFB3PFKFB4ROCK1NPSR1 | |
| SCHEMBL14435191 | 0.78 | MAPT (0.56) | MAPTKEAP1NFE2L2PFKFB3PFKFB4 | |
| SCHEMBL30693720 | 0.78 | PRNP (0.49) | MAPTPTGDR2KDM4EALDH1A1KMT2A | |
| SCHEMBL586189 | 0.78 | PRNP (0.49) | MAPTPTGDR2KDM4EALDH1A1KMT2A | |
| SCHEMBL11256326 | 0.77 | MAPT (0.54) | MAPTPFKFB3PFKFB4ROCK1NPSR1 | |
| SCHEMBL6984802 | 0.77 | MAPT (0.54) | MAPTPFKFB3PFKFB4ROCK1NPSR1 | |
| SCHEMBL11060333 | 0.77 | PTGDR2 (0.50) | MAPTKEAP1NFE2L2PTGDR2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20070071688-A1 | Pharmaceutical compositions for transdermal administration of anti-inflammatory agents | SANOFI-AVENTIS (FR) | 2007-03-29 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-20030152611-A1 | Pharmaceutical compositions for transdermal administration of anti-inflammatory agents | SANOFI-AVENTIS (FR) | 2003-08-14 | — | — | US | claimed |
| EP-1283704-A2 | PHARMACEUTICAL COMPOSITIONS FOR TRANSDERMAL ADMINISTRATION OF ANTI-INFLAMMATORY AGENTS | Sanofi-Aventis (FR) | 2003-02-19 | — | — | EP | claimed |
| WO-2001085143-A2 | PHARMACEUTICAL COMPOSITIONS FOR TRANSDERMAL ADMINISTRATION OF ANTI-INFLAMMATORY AGENTS | SANOFI-SYNTHELABO (FR) | 2001-11-15 | — | — | WO | claimed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140154313-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2014-06-05 | — | — | US | disclosed |
| EP-0010061-B1 | PHARMACEUTICAL PREPARATIONS CONTAINING A MOLLUSC EXTRACT | Mc Farlane, Stuart John (NZ) | 1983-07-13 | — | — | EP | disclosed |
| US-4362738-A | ANTIINFLAMMATORIES | DR. KARL THOMAE GMBH (DE) | 1982-12-07 | — | — | US | disclosed |
| EP-0024282-A1 | Benzoyl derivatives, their preparation and their use as medicines | Dr. Karl Thomae GmbH (DE) | 1981-03-04 | — | — | EP | disclosed |
| WO-1980000661-A1 | PHARMACEUTICAL PREPARATIONS | CROFT J (NZ) | 1980-04-17 | — | — | WO | disclosed |
| EP-0010061-A1 | Pharmaceutical preparations containing a mollusc extract | Mc Farlane, Stuart John (NZ) | 1980-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070071688-A1 | Pharmaceutical compositions for transdermal administration of anti-inflammatory agents | CUTA, MMP1, TSLP | MAPT 1653/4885KEAP1 4552/4885NFE2L2 1599/4885 |
| US-20030152611-A1 | Pharmaceutical compositions for transdermal administration of anti-inflammatory agents | CUTA, MMP1, MMP13 | MAPT 1876/4885KEAP1 4573/4885NFE2L2 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.